La Jolla Pharmaceutical Company (OQ:LJPC)

Business Focus: Bio Therapeutic Drugs

Jan 07, 2019 09:00 ET
La Jolla Pharmaceutical Company Highlights Recent Corporate Progress and Key Objectives
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today highlighted...
Jan 04, 2019 09:00 ET
La Jolla Pharmaceutical Company to Present at the 37th Annual J.P. Morgan Healthcare Conference
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Nov 06, 2018 08:35 ET
Research Report Identifies Exelon, La Jolla Pharmaceutical, Kennedy-Wilson, Fluidigm, Telefonica SA, and Cognex with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Exelon Corporation (NYSE:EXC), La Jolla Pharmaceutical Company...
Oct 24, 2018 16:01 ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2018
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Oct 18, 2018 16:01 ET
La Jolla Pharmaceutical Company to Release Third Quarter 2018 Financial Results on October 24, 2018
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Oct 16, 2018 07:25 ET
Recent Analysis Shows Professional Diversity Network, Quanex Building Products, HTG Molecular Diagnostics, La Jolla Pharmaceutical, Playa Hotels & Resorts N.V, and Plexus Market Influences — Renewed O
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Professional Diversity Network, Inc. (NASDAQ:IPDN), Quanex Building...
Aug 16, 2018 08:00 ET
Factors of Influence in 2018, Key Indicators and Opportunity within Celsion, Alpha and Omega Semiconductor, SP Plus, Merrimack Pharmaceuticals, La Jolla Pharmaceutical, and SPX — New Research Emphasiz
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Celsion Corporation (NASDAQ:CLSN), Alpha and Omega Semiconductor Limited...
Aug 08, 2018 16:01 ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Corporate Progress
La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Aug 03, 2018 09:00 ET
La Jolla Pharmaceutical Company Announces Receipt of New Technology Add-on Payment Coverage for GIAPREZA
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Aug 01, 2018 17:39 ET
La Jolla Pharmaceutical Company to Release Second Quarter 2018 Financial Results and Host a Webcasted Conference Call on August 8, 2018
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
Jun 25, 2018 09:00 ET
La Jolla Pharmaceutical Company Announces European Medicines Agency Validation of Marketing Authorisation Application for GIAPREZA™ (angiotensin II)
La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
May 21, 2018 08:25 ET
Recent Analysis Shows Engility, La Jolla Pharmaceutical, Freshpet, At Home Group, Denny's, and SP Plus Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Engility Holdings, Inc. (NYSE:EGL), La Jolla Pharmaceutical Company...
May 17, 2018 13:00 ET
La Jolla Pharmaceutical Company Announces LJPC-401 Presentations at 23rd Congress of the European Hematology Association
La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
May 10, 2018 16:46 ET
La Jolla Pharmaceutical Company Announces $125 Million Royalty Financing Agreement with HealthCare Royalty Partners
La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today...
May 10, 2018 16:45 ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress
La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced...
May 01, 2018 17:15 ET
CalciMedica Names Two Senior Executives to its Board of Directors
LA JOLLA, Calif., May 1, 2018 /PRNewswire/ -- CalciMedica announced that it named two independent members to its Board of Directors, Lakhmir Chawla, MD, currently Chief Medical Officer of La Jolla Pharmaceuticals Company (NASDAQ: LJPC), and Christopher Krueger, JD, MBA, a co-founder and Chief Business Officer of Escalier Biosciences. The two new Board members bring extensive clinical development and financing/transaction experience, respectively, to CalciMedica as it advances its novel acute pancreatitis agent, CM4620, through clinical development. ...
Mar 23, 2018 07:40 ET
Market Trends Toward New Normal in La Jolla Pharmaceutical, AquaVenture, Duluth, Community Bank System, Cubic, and TrustCo Bank Corp NY — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, March 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of La Jolla Pharmaceutical Company (NASDAQ:LJPC), AquaVenture...
Mar 22, 2018 16:01 ET
La Jolla Pharmaceutical Company Announces Launch of GIAPREZA™ (angiotensin II) in the United States
SAN DIEGO, March 22, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that GIAPREZA™ (angiotensin II), injection for intravenous infusion, is now commercially available. In December 2017, GIAPREZA was approved by the U.S. Food and Drug Administration (FDA) to...
Mar 15, 2018 08:00 ET
La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock
SAN DIEGO, March 15, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the pricing...
Mar 14, 2018 16:01 ET
La Jolla Pharmaceutical Company Announces $100 Million Public Offering of Common Stock
SAN DIEGO, March 14, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced a registered...
Mar 06, 2018 14:40 ET
GIAPREZA™ (angiotensin II) Significantly Improved Survival and Reduced Time on Renal Replacement Therapy in Patients with Acute Kidney Injury
Analyses to Be Presented in Oral and Poster Sessions at The 23rd International Conference on Advances in Critical Care Nephrology AKI & CRRT 2018
Feb 25, 2018 09:00 ET
GIAPREZA™ (angiotensin II) Significantly Improved Survival of Patients with High APACHE II Scores in ATHOS-3 Study
Analysis to Be Presented in Oral Session at the Society of Critical Care Medicine’s 47th Critical Care Congress
Feb 22, 2018 17:17 ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress
SAN DIEGO, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for...
Feb 21, 2018 09:00 ET
La Jolla Pharmaceutical Company Announces the Treatment of First Patient in GIAPREZA™ (angiotensin II) Pediatric Study
SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that the first pediatric patient has been treated in LJ501-CRH02, La Jolla’s open-label study of GIAPREZATM (angiotensin II), injection for intravenous infusion, in...
Jan 24, 2018 08:00 ET
Consolidated Research: 2018 Summary Expectations for Freshpet, eHealth, SEACOR, La Jolla Pharmaceutical, Rogers, and On Assignment — Fundamental Analysis, Key Performance Indications
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Freshpet, Inc. (NASDAQ:FRPT), eHealth, Inc. (NASDAQ:EHTH),...
Dec 21, 2017 18:15 ET
La Jolla Pharmaceutical Company Announces FDA Approval of Giapreza™ (angiotensin II)
Giapreza increases blood pressure in adults with septic or other distributive shock
Dec 18, 2017 09:00 ET
La Jolla Pharmaceutical Company Announces Initiation of Multicenter, Randomized, Phase 2 Clinical Study of LJPC‑401 in Patients with Hereditary Hemochromatosis
SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) today announced the initiation of LJ401-HH01, a Phase 2 clinical study of LJPC‑401 (synthetic human hepcidin) in patients with hereditary...
Dec 04, 2017 09:00 ET
La Jolla Pharmaceutical Company Announces Initiation of Pivotal Clinical Study of LJPC‑401 in Patients with Beta Thalassemia
SAN DIEGO, Dec. 04, 2017 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) today announced the initiation of a pivotal clinical study of LJPC‑401 (synthetic human hepcidin) in patients with transfusion-dependent beta thalassemia...
Oct 26, 2017 17:10 ET
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported financial results for the three and nine months ended September 30, 2017